Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why I do not treat patients for mild disease.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2016

Hézode Christophe

Abstract excerpt

The short-term prognosis of patients with chronic hepatitis C and mild disease is excellent. Monitoring of the progression of fibrosis is easy to perform with non-invasive tests. Current all-oral interferon (IFN)- and ribavirin (RBV)-free regimens offer sustained viral response (SVR) rates of more than 90% as well as 12-weeks of treatment for most patients with mild disease. Several DAA combinations can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Cirrhosis
Share to Ribavirin
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Cost-Benefit Analysis

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C, Chronic

Source

Identifiers

PMID: 26725892
DOI: 10.1111/liv.13019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why I do not treat patients for mild disease.PMID 26725892Read ↗

Why do I treat my patients with mild hepatitis C?Semantic proximity Read ↗

[Chronic hepatitis C: patients with mild disease].Semantic proximity Read ↗

Preparing the patient for success: treat or wait?Semantic proximity Read ↗

Into the light: strategies for battling hepatitis C.Semantic proximity Read ↗

Chronic hepatitis C genotype 1 virus: who should wait for treatment?Semantic proximity Read ↗

Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.Semantic proximity Read ↗

How severe is chronic hepatitis with HCV genotype 1b? A study of 1,220 cases on the waiting list for antiviral therapy in Romania.Semantic proximity Read ↗

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Semantic proximity Read ↗

Non-responders to previous treatment for hepatitis C.Semantic proximity Read ↗

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.Semantic proximity Read ↗

What to do when standard therapy fails.Semantic proximity Read ↗

[Difficult-to-treat patients with chronic hepatitis C].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.